Price (delayed)
$1.6
Market cap
$104.8M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.06
Enterprise value
$78.84M
Regulus Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop
There are no recent dividends present for RGLS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.